Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has patented compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.
Researchers from Astrazeneca plc reported preclinical data for AZD-8421, a selective cyclin-dependent kinase 2 (CDK2) inhibitor, currently being evaluated in early-phase clinical trials as a treatment for solid tumors.
Blueprint Medicines Corp. recently disclosed the chemical structure of BLU-222, an oral, potent and highly selective inhibitor of the CDK2 kinase, being developed for the potential treatment of cancers with CCNE1 amplification and/or cyclin E overexpression, such as HR-positive HER2-negative breast cancer resistant to CDK4/6 inhibitor therapy.
Investigators at Incyte Corp. have reported details on the discovery and preclinical characterization of new potent and selective inhibitors of cyclin-dependent kinase 2 (CDK2) as potential anticancer candidates.
